HemoSense Names Conan Li to VP of Research & Development.SAN JOSE, Calif. -- HemoSense, Inc. (AMEX AMEX See: American Stock Exchange :HEM) today announced that Conan Li, Ph.D., 55, has joined the Company as vice president, research and development. Dr. Li replaces Mags McInerney, Ph.D., who resigned in November 2006 to pursue other business opportunities. "Conan brings to HemoSense more than 25 years of impressive product development and leadership experience at top-tier diagnostic companies, as well as a distinguished scientific background," said Jim Merselis, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of HemoSense. "Throughout his career Conan has played instrumental roles in the diagnostics space including his contributions through senior management positions, committees and boards and at various key companies and institutions including Roche, Quest Diagnostics and Abbott Laboratories. As we look to enhance our current product offering and broaden our technology platform, we believe Conan's expertise will further augment our R&D capabilities." Most recently Dr. Li was R&D manager of molecular diagnostics and a member of the Life Sciences R&D Council at Agilent Technologies Inc., where he led a multidisciplinary team to complete novel diagnostic assays and instituted the automation of a manual assay procedure. Prior to that, he led the development of in vitro in vitro /in vi·tro/ (in ve´tro) [L.] within a glass; observable in a test tube; in an artificial environment. in vi·tro adj. In an artificial environment outside a living organism. test platforms as the senior vice president and chief technology officer of VaxDesign Corporation, a privately held biotechnology company. He was also the director of the Advanced Technology Group at Quest Diagnostics Nichols Institute, where his responsibilities included directing new technology R&D, developing strategic alliances and new business development. During his career Dr. Li has also served as vice president of product development at Cellomics, Inc., a biotechnology instrumentation company; vice president of science and research at Xylum Corporation, a start up medical device company; and senior biochemist of the Diagnostics Division at Abbott Laboratories where he was responsible for the development of several key patents. Dr. Li has also served on numerous committees and boards including as the co-chairman of the Biorheology Scientific and Standardization Committee of the International Society of Hemostasis hemostasis /he·mo·sta·sis/ (he?mo-sta´sis) (he-mos´tah-sis) 1. the arrest of bleeding by the physiological properties of vasoconstriction and coagulation or by surgical means. 2. and Thrombosis and as an advisor to the National Committee on Clinical Laboratory Standards Subcommittee of Point-of-Care Coagulation coagulation (kōăg'y  lā`shən), the collecting into a mass of minute particles of a solid dispersed throughout a liquid (a sol), usually followed by the precipitation or Testing. Dr. Li holds an MBA MBA abbr. Master of Business Administration Noun 1. MBA - a master's degree in business Master in Business, Master in Business Administration from Cornell University, a Ph.D. in biophysics biophysics, application of various methods and principles of physical science to the study of biological problems. In physiological biophysics physical mechanisms have been used to explain such biological processes as the transmission of nerve impulses, the muscle from Harvard University and a bachelor's of science degree in physics from the Massachusetts Institute of Technology Massachusetts Institute of Technology, at Cambridge; coeducational; chartered 1861, opened 1865 in Boston, moved 1916. It has long been recognized as an outstanding technological institute and its Sloan School of Management has notable programs in business, . About HemoSense HemoSense is a point-of-care diagnostic healthcare company that develops, manufactures and markets easy-to-use, handheld blood coagulation systems for monitoring patients taking warfarin warfarin (wôr`fərĭn), anticoagulant used to treat blood clots. In large doses it causes bleeding. Warfarin, mixed with bait, is used in rodent control. warfarin Anticoagulant drug, marketed as Coumadin. . The HemoSense INRatio[R] system, used by healthcare professionals and patients themselves, consists of a small monitor and disposable test strips. It provides accurate and convenient measurement of blood clotting blood clotting, process by which the blood coagulates to form solid masses, or clots. In minor injuries, small oval bodies called platelets, or thrombocytes, tend to collect and form plugs in blood vessel openings. time, or PT/INR values. Routine measurements of PT/INR are necessary for the safe and effective management of the patient's warfarin dosing. INRatio is sold in the United States and internationally. For more information, visit www.hemosense.com. This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Statements in this press release regarding the Company's ability to enhance its current product offering and broaden its technology platform may be "forward-looking statements" that involve risks and uncertainties. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties which may cause the actual results to differ materially from the statements contained herein. Further information on the Company's business and risk factors are detailed in its filings with the Securities and Exchange Commission, including its 2006 Form 10-K filed on December 27, 2006. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. HemoSense[R] and INRatio[R] are registered trademarks of HemoSense, Inc. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion